Imaging synucleinopathies

Brooks, David J.; Tambasco, Nicola

doi:10.1002/mds.26547

Cited by 35 publications

(31 citation statements)

References 109 publications

(207 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, EEG is a low‐cost and widely available tool, and most equipment automatically provides MF computation. As for 123 I‐FP‐CIT‐SPECT, it is increasingly used to confirm a diagnosis in doubtful cases, and nuclear medicine departments largely employ semiquantification tools . Among the latter, we applied one that can be freely downloaded, but others are available.…”

Section: Discussionmentioning

confidence: 99%

Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Although the MRI scanning time for a single patient (DTI 4 min 22 sec, ASL 4 min 29 sec) does not seem short enough in our study, these MRI techniques are still promising alternative tools in clinical practice. Importantly, various MRI technologies have shown great potential value in identifying dopaminergic neuron loss, neural fiber degeneration, pathological perfusion reduction, iron deposition, structural atrophy and altered energy metabolism for early stage PD diagnosis and evaluation of disease severity 33 34 35 36 .…”

Section: Discussionmentioning

confidence: 99%

Combined Diffusion Tensor Imaging and Arterial Spin Labeling as Markers of Early Parkinson’s disease

Wei

Yan

Chen

et al. 2016

Sci Rep

View full text Add to dashboard Cite

This study aimed to identify a PD-specific MRI pattern using combined diffusion tensor imaging (DTI) and arterial spin labeling (ASL) to discriminate patients with early PD from healthy subjects and evaluate disease status. Twenty-one early and 22 mid-late PD patients, and 22 healthy, age/gender-matched controls underwent 3-T MRI with apparent diffusion coefficient (ADC), fractional anisotropy (FA), fiber number (FN) and cerebral blood flow (CBF) measurements. We found that compared with healthy subjects, there was a profound reduction in FN passing through the SN in PD. FA in the SN and CBF in the caudate nucleus were inversely correlated with motor dysfunction. A negative correlation was observed between FA in the hippocampus (Hip) and the NMSS-Mood score, whereas CBF in the Hip and the prefrontal cortex(PFC) correlated with declined cognition. Stratified five-fold cross-validation identified FA in the SN(FA-SNAv), CBF in the PFC(CBF-PFCAv) and FA in the parietal white matter(FA-PWMAv), and the combination of these measurements offered relatively high accuracy (AUC 0.975, 90% sensitivity and 100% specificity) in distinguishing those with early PD from healthy subjects. We demonstrate that the decreased FNs through SN in combination with changes in FA-SNAv, CBF-PFCAv and FA-PWMAv values might serve as potential markers of early-stage PD.

show abstract

“…The presynaptic DAT signal is depressed in the posterior putamen early in the course of Parkinson's disease and demonstrates characteristic asymmetry in the pattern of signal loss (Brooks and Tambasco, 2016). The level of striatal DAT binding in PD correlates with contralateral clinical measures of bradykinesia and rigidity (Benamer et al, 2000b), as well as with the degree of dopaminergic cell loss in the substantia nigra post-mortem (Kraemmer et al, 2014).…”

Section: Neuroimaging In Pre-motor Parkinson'smentioning

confidence: 99%

“…Whilst MRI is commonly used in clinical practice as an adjunctive test in the differential diagnosis of parkinsonian syndromes, reliable identification of the specific neurodegenerative signature of idiopathic PD has not been possible with routine imaging sequences (Brooks and Tambasco, 2016, Rizzo et al, 2016a). However, the capacity to resolve the key brainstem structures and identify relevant pathological changes has improved with the advent of high field strength MRI scanners and sequences targeting specific molecular processes.…”

Section: Neuroimaging In Pre-motor Parkinson'smentioning

confidence: 99%

Neuroimaging in pre-motor Parkinson's disease

Barber

Klein

Mackay

et al. 2017

NeuroImage: Clinical

View full text Add to dashboard Cite

The process of neurodegeneration in Parkinson's disease begins long before the onset of clinical motor symptoms, resulting in substantial cell loss by the time a diagnosis can be made. The period between the onset of neurodegeneration and the development of motoric disease would be the ideal time to intervene with disease modifying therapies. This pre-motor phase can last many years, but the lack of a specific clinical phenotype means that objective biomarkers are needed to reliably detect prodromal disease. In recent years, recognition that patients with REM sleep behaviour disorder (RBD) are at particularly high risk of future parkinsonism has enabled the development of large prodromal cohorts in which to investigate novel biomarkers, and neuroimaging has generated some of the most promising results to date. Here we review investigations undertaken in RBD and other pre-clinical cohorts, including modalities that are well established in clinical Parkinson's as well as novel imaging methods. Techniques such as high resolution MRI of the substantia nigra and functional imaging of Parkinsonian brain networks have great potential to facilitate early diagnosis. Further longitudinal studies will establish their true value in quantifying prodromal neurodegeneration and predicting future Parkinson's.

show abstract

Imaging synucleinopathies

Cited by 35 publications

References 109 publications

Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers

Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers

Combined Diffusion Tensor Imaging and Arterial Spin Labeling as Markers of Early Parkinson’s disease

Neuroimaging in pre-motor Parkinson's disease

Contact Info

Product

Resources

About